Studies have shown that although the positive rate of PD‐L1 in tumor specimens with EGFR/ALK mutations is high, the ratio of high levels of CD8+TILs is very low,149 which limits the antitumor effect of anti‐PD‐1/PD‐L1 monoclonal antibody. The gene discussed is CD8A; the disease is neoplasm.